文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

芦可替尼治疗COVID-19相关急性呼吸窘迫综合征的随机3期试验

Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.
PubMed 文献 · Crit Care Med · 2022-10-13
一句话结论机械通气的COVID-19相关ARDS患者中,芦可替尼15 mg或5 mg每日两次较安慰剂未显著降低28天死亡率,试验因提前终止而把握度不足。

这项3期随机双盲安慰剂对照试验在美国29个中心和俄罗斯4个中心纳入211例机械通气的COVID-19相关ARDS患者(年龄24-87岁),按2:2:1随机接受芦可替尼15 mg、5 mg每日两次或安慰剂,均联合标准治疗。主要终点28天死亡率:芦可替尼15 mg组51%(39/77,95%CI 39-62%),5 mg组53%(45/85,95%CI 42-64%),安慰剂组70%(33/47,95%CI 55-83%);15 mg组OR 0.46(95%CI 0.201-1.028,单侧P=0.029),5 mg组OR 0.42(95%CI 0.171-1.023,单侧P=0.028),均未达到预设的单侧P<0.025显著性阈值。芦可替尼15 mg组在无呼吸机、无ICU、无血管活性药物天数等次要终点上较安慰剂有数值上的改善。总体及严重治疗中出现的不良事件发生率在各组间相似。

要点

  • 机械通气的COVID-19相关ARDS患者中,芦可替尼15 mg每日两次组28天死亡率为51%(39/77),安慰剂组为70%(33/47),OR 0.46(95%CI 0.201-1.028),单侧P=0.029,未达到P<0.025的显著性阈值。
  • 芦可替尼5 mg每日两次组28天死亡率为53%(45/85),安慰剂组为70%(33/47),OR 0.42(95%CI 0.171-1.023),单侧P=0.028,同样未达到显著性阈值。
  • 芦可替尼15 mg组在无呼吸机天数、无ICU天数、无血管活性药物天数等次要终点上较安慰剂有数值上的改善。
  • 总体及严重治疗中出现的不良事件发生率在芦可替尼组与安慰剂组间相似。
  • 作者认为该试验因提前终止而把握度不足,观察到的28天死亡率降低未达统计学显著。

适用人群与场景

  • 年龄≥12岁、因严重急性呼吸综合征冠状病毒2感染住院、机械通气且随机化前6小时内PaO2/FiO2≤300 mmHg的患者。

诊断标准与关键阈值

  • 纳入标准:年龄≥12岁;住院且严重急性呼吸综合征冠状病毒2感染;机械通气;随机化前6小时内PaO2/FiO2≤300 mmHg。
  • 主要终点显著性阈值:单侧P<0.025。

处置流程与药物剂量

  • 芦可替尼15 mg每日两次口服,联合标准治疗。
  • 芦可替尼5 mg每日两次口服,联合标准治疗。
  • 安慰剂每日两次,联合标准治疗。

研究设计与关键结果

  • 研究类型:3期随机、双盲、安慰剂对照试验(RUXCOVID-DEVENT;NCT04377620)。
  • 研究地点:美国29个中心和俄罗斯4个中心,共211例患者随机化(芦可替尼15 mg组n=77,5 mg组n=87,安慰剂组n=47),年龄范围24-87岁。
  • 随机化时27%(58/211)的患者ARDS分类为重度;90%(190/211)接受合并糖皮质激素治疗。
  • 主要终点28天死亡率:芦可替尼15 mg组51%(39/77;95%CI 39-62%),5 mg组53%(45/85;95%CI 42-64%),安慰剂组70%(33/47;95%CI 55-83%)。
  • 芦可替尼15 mg组 vs 安慰剂组:OR 0.46(95%CI 0.201-1.028),单侧P=0.029;5 mg组 vs 安慰剂组:OR 0.42(95%CI 0.171-1.023),单侧P=0.028;均未显著降低28天死亡率。
  • 次要终点:芦可替尼15 mg组较安慰剂组在无呼吸机天数、无ICU天数、无血管活性药物天数等方面有数值上的改善。
  • 安全性:总体及严重治疗中出现的不良事件发生率在各治疗组间相似。

证据类型、等级与局限

  • 证据类型:随机对照试验(3期、双盲、安慰剂对照)。
  • 局限:试验因提前终止而把握度不足(原文结论明确提及)。

对床旁实践的改变

  • 作者认为,在机械通气的COVID-19相关ARDS患者中,芦可替尼15 mg或5 mg每日两次较安慰剂观察到的28天死亡率降低未达统计学显著;该试验因提前终止而把握度不足。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Evaluate the safety and efficacy of the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib in COVID-19-associated acute respiratory distress syndrome requiring mechanical ventilation.

DESIGN: Phase 3 randomized, double-blind, placebo-controlled trial Ruxolitinib in Participants With COVID-19-Associated Acute Respiratory Distress Syndrome Who Require Mechanical Ventilation (RUXCOVID-DEVENT; NCT04377620).

SETTING: Hospitals and community-based private or group practices in the United States (29 sites) and Russia (4 sites).

PATIENTS: Eligible patients were greater than or equal to 12 years old, hospitalized with severe acute respiratory syndrome coronavirus 2 infection, and mechanically ventilated with a Pa o2 /F io2 of less than or equal to 300 mm Hg within 6 hours of randomization.

INTERVENTIONS: Patients were randomized 2:2:1 to receive twice-daily ruxolitinib 15 mg, ruxolitinib 5 mg, or placebo, each plus standard therapy.

MEASUREMENTS AND MAIN RESULTS: The primary endpoint, 28-day mortality, was tested for each ruxolitinib group versus placebo using a mixed-effects logistic regression model and one-tailed significance test (significance threshold: p < 0.025); no type 1 error was allocated to secondary endpoints. Between May 24, 2020 and December 15, 2020, 211 patients (age range, 24-87 yr) were randomized (ruxolitinib 15/5 mg, n = 77/87; placebo, n = 47). Acute respiratory distress syndrome was categorized as severe in 27% of patients (58/211) at randomization; 90% (190/211) received concomitant steroids. Day-28 mortality was 51% (39/77; 95% CI, 39-62%) for ruxolitinib 15 mg, 53% (45/85; 95% CI, 42-64%) for ruxolitinib 5 mg, and 70% (33/47; 95% CI, 55-83%) for placebo. Neither ruxolitinib 15 mg (odds ratio, 0.46 [95% CI, 0.201-1.028]; one-sided p = 0.029) nor 5 mg (odds ratio, 0.42 [95% CI, 0.171-1.023]; one-sided p = 0.028) significantly reduced 28-day mortality versus placebo. Numerical improvements with ruxolitinib 15 mg versus placebo were observed in secondary outcomes including ventilator-, ICU-, and vasopressor-free days. Rates of overall and serious treatment-emergent adverse events were similar across treatments.

CONCLUSIONS: The observed reduction in 28-day mortality rate between ruxolitinib and placebo in mechanically ventilated patients with COVID-19-associated acute respiratory distress syndrome was not statistically significant; however, the trial was underpowered owing to early termination.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rein L, Calero K, Shah R, et al. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome. Crit Care Med. 2022. PMID: 36226977. doi:10.1097/CCM.0000000000005682

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。